Target intelligence / Profile preview

Polyunsaturated phospholipid domain (PUFA-PL domain)

Target
PUFA-PL domain
Molecular classification
Lipid domain, Membrane component, Cellular structure
01

Overview

Polyunsaturated phospholipid domains are specialized regions within biological membranes characterized by a high concentration of phospholipids containing polyunsaturated fatty acids (PUFAs), such as arachidonic acid and docosahexaenoic acid. These domains are essential for maintaining membrane fluidity and facilitating dynamic processes like vesicle trafficking, endocytosis, and the rapid signaling required in neuronal synapses (PMID: 25172131). Unlike rigid lipid rafts, PUFA-rich domains are highly flexible and disordered, providing the necessary environment for the conformational changes of various membrane-bound proteins (PMID: 28461168). In clinical contexts, these domains are the primary substrates for lipid peroxidation during ferroptosis, an iron-dependent form of regulated cell death that is increasingly targeted in cancer therapy (PMID: 31160817). Therapeutic strategies involve either the induction of lipid peroxidation to kill cancer cells using agents like RSL3 or the protection of these domains using antioxidants like Ferrostatin-1 to treat neurodegenerative and ischemic diseases (PMID: 22595070). Understanding the spatial organization and chemical vulnerability of these domains is crucial for developing precision medicines that modulate cell survival through membrane lipid manipulation.

Other names
PUFA-rich membrane domainsPolyunsaturated fatty acid-containing phospholipid domainsNon-raft lipid domainsDisordered membrane domainsPUFA-PL domains
02

Mechanism of action

Modulation of membrane biophysical properties and serving as the primary site for iron-dependent lipid peroxidation during ferroptotic cell death (PMID: 31160817).

03

Biological functions

Membrane fluidity regulationVesicle traffickingSignal transductionFerroptosis substrateEndocytosis
04

Disease associations

CancerNeurodegenerative diseaseInflammationIschemia-reperfusion injury
05

Safety considerations

Potential for systemic oxidative damageAlteration of global membrane integrityInterference with normal synaptic vesicle recycling
06

Interacting drugs

Ferrostatin-1

6 more in the full profile.

07

Biomarkers

Malondialdehyde (MDA)4-hydroxynonenal (4-HNE)C11-BODIPY 581/591Oxidized phosphatidylethanolamine

Beyond the preview

Go deeper on Polyunsaturated phospholipid domain (PUFA-PL domain).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Polyunsaturated phospholipid domain (PUFA-PL domain).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call